LH - Laboratory Corporation of America Holdings
NYSE
->
Healthcare
->
Diagnostics & Research
Burlington,
United States
Type: Equity
LH price evolution
LH
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $265.1 | $99.3 | $536.8 | |
| Short term investments | ||||
| Net receivables | $2224.8 | $2246.4 | $2204.1 | $2098.7 |
| Inventory | $483.1 | $441.8 | $475 | $474.6 |
| Total current assets | $4909.9 | $3571.3 | $3456.5 | $3765.4 |
| Long term investments | $17.5 | $17.7 | $26.9 | |
| Property, plant & equipment | $3050 | $2932.5 | $2897.8 | $2911.8 |
| Goodwill & intangible assets | $9552.2 | $9613 | $9484.5 | |
| Total noncurrent assets | $13141 | $13074.5 | $12959.7 | |
| Total investments | $17.5 | $17.7 | $26.9 | |
| Total assets | $18612.5 | $16712.3 | $16531 | $16725.1 |
| Current liabilities | ||||
| Accounts payable | $660.9 | $760.6 | $695.5 | $827.5 |
| Deferred revenue | $388.3 | $377.5 | $421.7 | |
| Short long term debt | $2208.3 | $2219.2 | $1172 | |
| Total current liabilities | $3412 | $4064.7 | $3941.5 | $3225.2 |
| Long term debt | $5427.3 | $3766.8 | $3124.7 | $4133.3 |
| Total noncurrent liabilities | $4626.8 | $4614.7 | $5609.4 | |
| Total debt | $5975.1 | $5968.5 | $5954.2 | |
| Total liabilities | $10442.3 | $8691.5 | $8571.4 | $8850.1 |
| Shareholders' equity | ||||
| Retained earnings | $8275.8 | $8177.6 | $8055.3 | $7888.2 |
| Other shareholder equity | -$113.2 | -$192 | -$185.4 | -$59.3 |
| Total shareholder equity | $8005.8 | $7959.6 | $7875 | |
| (in millions $) | 31 Jan 2025 | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $536.8 | $430 | $1472.7 | |
| Short term investments | ||||
| Net receivables | $2098.7 | $3017.4 | $2978.3 | |
| Inventory | $474.6 | $470.6 | $401.4 | |
| Total current assets | $3765.4 | $4625 | $5330.5 | |
| Long term investments | $26.9 | $65.7 | $60.9 | |
| Property, plant & equipment | $2911.8 | $2956.2 | $2815.4 | |
| Goodwill & intangible assets | $9484.5 | $12067.9 | $11694.4 | |
| Total noncurrent assets | $12959.7 | $15530.1 | $15054.9 | |
| Total investments | $26.9 | $65.7 | $60.9 | |
| Total assets | $16725.1 | $20155.1 | $20385.4 | |
| Current liabilities | ||||
| Accounts payable | $827.5 | $934.8 | $621.3 | |
| Deferred revenue | $421.7 | $582.1 | $558.5 | |
| Short long term debt | $1172 | $492.8 | $199 | |
| Total current liabilities | $3225.2 | $3078.5 | $2782.9 | |
| Long term debt | $4133.3 | $5122.4 | $6143.6 | |
| Total noncurrent liabilities | $5609.4 | $6961.1 | $7308.5 | |
| Total debt | $5954.2 | $6294.9 | $6342.6 | |
| Total liabilities | $8850.1 | $10058.5 | $10091.4 | |
| Shareholders' equity | ||||
| Retained earnings | $7888.2 | $10581.7 | $10456.8 | |
| Other shareholder equity | -$59.3 | -$493.2 | -$191.9 | |
| Total shareholder equity | $7875 | $10096.6 | $10273.4 | |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3282 | $3176.6 | $3033.3 | |
| Cost of revenue | ||||
| Gross Profit | $904.4 | $897.3 | $821.4 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $632.3 | $568.5 | $592.1 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $41 | $69.1 | $19.7 | |
| Interest expense | -$59.4 | -$43.9 | -$42.5 | |
| Net income | ||||
| Net income | $169.3 | $228 | -$167.1 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12161.6 | $14876.8 | $16120.9 | $13978.5 |
| Cost of revenue | $10491.7 | $10496.6 | $9025.7 | |
| Gross Profit | $3364.9 | $4385.1 | $5624.3 | $4952.8 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $1996.6 | $1952.1 | $1729.3 | |
| Total operating expenses | $2241.2 | $2611.2 | $2364.8 | $2507.4 |
| Operating income | $1773.9 | $3259.5 | $2445.4 | |
| Income from continuing operations | ||||
| EBIT | $1761.4 | $3336.5 | $2425.6 | |
| Income tax expense | $188.5 | $302 | $747.1 | $662.1 |
| Interest expense | -$172.2 | $180.3 | $212.1 | $207.4 |
| Net income | ||||
| Net income | $418 | $1279.1 | $2377.3 | $1556.1 |
| Income (for common shares) | $1279.1 | $2377.3 | $1556.1 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | $205.3 | |||
| Operating activities | ||||
| Depreciation | $201.4 | |||
| Business acquisitions & disposals | -$33.9 | |||
| Stock-based compensation | $30.8 | |||
| Total cash flows from operations | $561.1 | |||
| Investing activities | ||||
| Capital expenditures | -$128.2 | |||
| Investments | -$23 | |||
| Total cash flows from investing | -$1157.2 | -$185 | -$393.1 | -$1171.5 |
| Financing activities | ||||
| Dividends paid | -$183 | -$60.4 | -$62.1 | -$254 |
| Sale and purchase of stock | -$123.1 | |||
| Net borrowings | -$22.6 | |||
| Total cash flows from financing | $1326.6 | -$210 | -$11.7 | -$59.3 |
| Effect of exchange rate | $2.5 | -$0.3 | -$2.9 | $9.9 |
| Change in cash and equivalents | $980.5 | $165.8 | -$437.5 | $106.8 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $1279.1 | $2377.3 | $1556.1 | |
| Operating activities | ||||
| Depreciation | $828.3 | $940 | $825 | |
| Business acquisitions & disposals | -$1162.4 | -$496.9 | -$267.6 | |
| Stock-based compensation | $144.1 | $153.7 | $111.7 | |
| Total cash flows from operations | $1955.9 | $3109.6 | $2135.3 | |
| Investing activities | ||||
| Capital expenditures | -$481.9 | -$460.4 | -$381.7 | |
| Investments | -$12.2 | -$14.6 | -$39.1 | |
| Total cash flows from investing | -$1171.5 | -$1652.2 | -$884.6 | -$643.2 |
| Financing activities | ||||
| Dividends paid | -$254 | -$195.2 | ||
| Sale and purchase of stock | -$1100 | -$1664.2 | -$78.6 | |
| Net borrowings | -$375 | -$412.2 | ||
| Total cash flows from financing | -$59.3 | -$1322.2 | -$2065.8 | -$517.4 |
| Effect of exchange rate | $9.9 | -$24.2 | -$7.3 | $8.6 |
| Change in cash and equivalents | $106.8 | -$1042.7 | $151.9 | $983.3 |
News
Fundamentals
| Market cap | $20.63B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 83.70M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 7.37% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.44 |
| Quick ratio | 1.30 |